Scientific advisers to the Centers for Disease Control and Prevention (CDC) voted Thursday to recommend the booster dose of Pfizer's COVID-19 vaccine only for people 65 and older. for those at high risk due to their health problems or their exposure to coronavirus in their jobs.
The pharmaceutical company Pfizer had requested to administer this booster to all those over 16 years of age, arguing that the immunity of the vaccine declines over time, but experts recommended limiting the scope of this immunization campaign, as the Administration of Food and Drug Administration (FDA).
The committee's recommendations are not binding, and CDC officials sometimes apply their own criteria, but their opinion is likely to determine the final decision.
The same happened in the case of the FDA: their advisers decided to limit the booster dose to these groups, and the federal agency followed their advice.
FDA clearance includes elderly people and also those over 18 years of age who are at high risk of becoming seriously ill from COVID-19 or suffering serious complications from exposure to the virus in their jobs, such as doctors and teachers.
